Vistagen Therapeutics (VTGN) Given a $6.00 Price Target at Oppenheimer
Several other research firms have also recently weighed in on VTGN. Maxim Group set a $6.00 price objective on shares of Vistagen Therapeutics and gave the stock a buy rating in a research report on Thursday, August 30th. Zacks Investment Research upgraded shares of Vistagen Therapeutics from a hold rating to a buy rating and set a $1.50 price objective on the stock in a research report on Thursday, August 30th. Chardan Capital reiterated a buy rating and set a $22.00 price objective on shares of Vistagen Therapeutics in a research report on Friday, June 29th. Finally, UBS Group assumed coverage on shares of Vistagen Therapeutics in a research report on Thursday, May 24th. They set an outperform rating and a $6.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus price target of $8.30.
Vistagen Therapeutics stock opened at $1.35 on Tuesday. Vistagen Therapeutics has a 1 year low of $0.69 and a 1 year high of $2.65.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Recommended Story: Hedge Funds
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.